Core Viewpoint - Zejing Pharmaceutical has entered into a global development and commercialization strategic cooperation and licensing option agreement with AbbVie for ZG006, which includes significant upfront and milestone payments, indicating strong potential for revenue growth and market expansion in oncology treatments [1][3]. Group 1: ZG006 Collaboration with AbbVie - The agreement grants AbbVie exclusive rights to develop and commercialize ZG006 outside Greater China, while Zejing retains rights within the region [3]. - Zejing has received an upfront payment of $100 million and may receive up to $60 million in milestone payments, with potential additional milestone payments of up to $1.075 billion if the licensing option is exercised [3]. - The collaboration is expected to enhance Zejing's innovation profile and international influence, providing more treatment options for global patients [3]. Group 2: Clinical Data and Progress of ZG006 - ZG006 is currently in clinical trials for small cell lung cancer and neuroendocrine cancer, showing promising efficacy and safety [4]. - In a Phase II trial for late-stage small cell lung cancer, ZG006 demonstrated an overall response rate (ORR) of 53.3% and a median progression-free survival (mPFS) of 7.03 months [4]. - In neuroendocrine cancer patients, the ORR was 38.5%, with a notable 66.7% in DLL3-positive patients [4]. Group 3: ZG005 Clinical Data and Development - ZG005 is advancing in clinical trials for liver cancer, neuroendocrine cancer, and cervical cancer, with a confirmed ORR of 40.9% and disease control rate (DCR) of 68.2% in cervical cancer patients [5]. - The drug has shown encouraging activity in early studies for advanced cervical cancer and liver cancer, indicating broad potential for combination therapies [5]. Group 4: Sales and Market Strategies - The injection of human thyroid-stimulating hormone β (Zesuning®) has been approved for post-surgical diagnosis in differentiated thyroid cancer, marking it as the first innovative product in this area in China [6]. - Zejing has partnered with Merck for exclusive promotion of Zesuning®, aiming to enhance its market presence in personalized diagnosis for thyroid cancer patients [6]. - The company’s Jikaxitini tablets have been included in the national medical insurance directory, expected to positively impact sales due to its classification as a first-line treatment in clinical guidelines [7]. Group 5: Financial Performance Forecast for 2025 - Zejing anticipates revenue between 796.49 million and 828.99 million yuan for 2025, representing a year-on-year increase of 49.45% to 55.55% [9]. - The revenue growth is primarily driven by the inclusion of recombinant thrombin in the national medical insurance directory and the commercialization of Jikaxitini [9]. - Despite the revenue increase, the company expects to report a net loss due to rising sales and research expenses [9].